Last updated: June 3, 2026
ViiV Healthcare Co. v. Gilead Sciences, Inc. | 1:18-cv-00224-CFC-CJB: Litigation Summary, Claims at Issue, and Expected Patent- and Launch-Impact
ViiV Healthcare brought suit against Gilead Sciences in a Delaware federal case over HIV antiretroviral intellectual property, docketed as 1:18-cv-00224-CFC-CJB. The filing followed ViiV’s portfolio protection strategy around its second-generation HIV regimen IP estate, with litigation centered on patent validity/enforceability and infringement allegations tied to Gilead’s late-stage product and/or ANDA-style regulatory posture.
What is the case background for ViiV v. Gilead 1:18-cv-00224-CFC-CJB?
The docket is ViiV Healthcare Company v. Gilead Sciences, Inc., 1:18-cv-00224-CFC-CJB, in the U.S. District Court for the District of Delaware. The case designation “CFC-CJB” identifies the assigned district judge and magistrate judge. ViiV is the plaintiff; Gilead is the defendant.
Forum and procedure indicators
- Court: U.S. District Court for the District of Delaware
- Case number: 1:18-cv-00224-CFC-CJB
- Parties: ViiV Healthcare Company (plaintiff) vs. Gilead Sciences, Inc. (defendant)
- Case type (inferred from structure of Delaware generic/IP docketing): Pharmaceutical patent infringement, including allegations of infringement of one or more listed patents and defenses of invalidity/non-infringement.
What the litigation is “about” at a high level
This lawsuit aligns with the common Delaware pattern for HIV small-molecule IP enforcement: patent assertions against a competitor’s product lifecycle activity, with infringement theories directed to composition, formulation, and/or method-of-use claims. In these cases, disputes typically track the asserted patent list and the defendant’s regulatory filings that triggered litigation.
Which patents were asserted in ViiV v. Gilead (1:18-cv-00224-CFC-CJB) and what claim types were targeted?
No actionable asserted-patent dataset is present in the provided input. A litigation summary that identifies the exact asserted patent numbers, claim numbers, and specific claim categories (composition, method-of-use, formulation, manufacturing) requires the complaint and/or infringement chart. Without the asserted-patent list and claim mapping, the analysis cannot be completed to a litigation-grade standard.
What did ViiV allege Gilead infringed in 1:18-cv-00224-CFC-CJB?
No actionable infringement-issue data is present in the provided input. A precise allegation summary must rest on complaint allegations and the infringement chart, including:
- the product(s) accused (active ingredient and dosage form)
- the specific product formulation or dosage route alleged to infringe
- the asserted patent claim limitations allegedly met by each accused product configuration
Without those details, any infringement narrative would be non-specific and not business-usable for licensing, diligence, or litigation risk.
How did Gilead respond: invalidity, non-infringement, and equitable defenses?
No actionable defense and procedural posture data is present in the provided input. A litigation analysis requires, at minimum:
- Gilead’s invalidity theories (anticipation, obviousness, §112 arguments, written description/enablement, indefiniteness)
- non-infringement construction positions
- any inequitable conduct or prosecution-history-estoppel assertions
- whether there were counterclaims (e.g., declaratory judgment invalidity/non-infringement)
What motions were decided in the case timeline for 1:18-cv-00224-CFC-CJB?
No docket-event timeline data is present in the provided input. A Bloomberg-style litigation summary typically enumerates:
- initial motion practice (claim construction, preliminary injunction request, stay motions)
- summary judgment rulings (if any)
- whether the case proceeded to trial
- any remands or interlocutory appeals to the Federal Circuit
Without docket entries or a motion list, the timeline cannot be reconstructed accurately.
Did the case reach claim construction, summary judgment, or trial in 1:18-cv-00224-CFC-CJB?
No procedural disposition data is present in the provided input. An accurate answer requires docket rulings (claim construction orders, dispositive motions, trial scheduling, or settlement dismissal entries).
What settlement or dismissal events occurred in ViiV v. Gilead (1:18-cv-00224-CFC-CJB)?
No settlement or termination data is present in the provided input. Litigation-grade settlement analysis depends on:
- whether the case settled
- the terms (launch date restrictions, covenant-not-to-sue, license scope, royalty rates, ongoing royalties)
- dismissal mechanism (with/without prejudice, stipulation dates)
- whether any patents were dropped or narrowed via amended complaints.
What is the Orange Book status and FDA pathway link to this litigation?
No Orange Book / FDA listing data is present in the provided input. For HIV products, exclusivity and patent listings are often the trigger for litigation. A correct analysis must map:
- the listed patents to the asserted patents
- the FDA application type (e.g., ANDA, 505(b)(2))
- whether the filing was Paragraph IV or a different certification
- whether exclusivity (NCE, 5-year, 7-year, pediatric, etc.) contributed to the litigation posture.
What does this litigation mean for generic or competitor launch timing?
No launch-impact details are present in the provided input. Business users typically need:
- the earliest potential launch date constrained by patent expiration and exclusivity
- any imposed “carve-out” or agreed launch timing via settlement
- risk of design-around and whether method-of-use or formulation claims survive.
A timing analysis cannot be completed without the asserted patents and their expiration dates, plus the case outcome or settlement terms.
How strong is the ViiV patent estate relative to Gilead’s contested product based on 1:18-cv-00224-CFC-CJB?
No patent list or merits outcome data is present in the provided input. Patent estate strength analysis requires:
- the number of asserted patents
- whether the patents are composition vs. method-of-use vs. formulation
- the litigation posture (Markman results, invalidity findings, infringement findings)
- any later cancellations or disclaimers.
Where does the dispute fit in the broader HIV IP landscape between ViiV and Gilead?
No cross-case or portfolio map data is present in the provided input. A credible “broader landscape” section requires:
- identification of the specific HIV products at issue
- mapping to known ViiV-Gilead battles (platform patents, co-formulation strategies, and method-of-use claims)
- the IP expiration and design-around feasibility for the relevant chemical series.
Key Takeaways
- The matter is docketed as ViiV Healthcare Company v. Gilead Sciences, Inc., 1:18-cv-00224-CFC-CJB in the District of Delaware.
- A complete litigation summary requires asserted-patent identification, claim chart details, and docket outcomes (motions, rulings, and termination events). None of that information is included in the provided input.
FAQs
- What is the court and docket format for 1:18-cv-00224-CFC-CJB?
- How do Delaware cases like this typically map asserted HIV patents to an accused competitor product?
- What are the usual dispositive milestones (Markman, summary judgment) for pharma patent cases in D. Del.?
- How does Paragraph IV filing posture generally drive litigation timing in HIV small-molecule disputes?
- What settlement terms commonly affect launch dates in US pharma patent cases?
References
No sources were provided in the input to cite.
